文献速递瓣膜外科

Trifecta瓣膜衰败机制与再干预策略:Perceval对比瓣中瓣TAVI

Mechanisms of Trifecta Valve Failure and Contemporary Approaches to Reintervention: Perceval vs Valve-in-Valve Transcatheter Aortic Valve Implantation.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2026-01-01

Trifecta中位耐久性4至9年,再手术率7.3%至16.9%,小尺寸瓣膜(19-21 mm)退化更快。衰败早期多为瓣叶沿支架柱撕裂或脱开,远期包括瓣叶钙化及流入道纤维脂肪性环形血管翳。推荐对肾功能受损、术后有效开口面积指数低及患者-人工瓣膜不匹配者密切超声随访;再干预时Perceval可能适合小自体瓣环,瓣中瓣TAVI因有效开口面积减小风险仅限选择病例。

要点

  • Trifecta中位耐久性4至9年,再手术率7.3%至16.9%。
  • 小尺寸瓣膜(19-21 mm)退化更快。
  • 肾功能受损、低EOA指数及PPM者应密切超声随访。

核心结论

  • Trifecta衰败与抗钙化化合物及瓣膜设计相关,早期为瓣叶沿支架柱撕裂或脱开,远期包括瓣叶钙化及流入道纤维脂肪性环形血管翳。
  • 再干预时,缝合less Perceval可能适合小自体瓣环,瓣中瓣TAVI因有效开口面积减小风险仅限选择病例。

主要发现

  • Trifecta中位耐久性4至9年,再手术率7.3%至16.9%。
  • 小尺寸瓣膜(19-21 mm)退化更快。
  • 衰败早期模式为瓣叶沿支架柱撕裂或脱开,远期包括瓣叶钙化及流入道纤维脂肪性环形血管翳。

关键数值与推荐

  • 推荐对Trifecta植入后肾功能受损、术后有效开口面积指数低及患者-人工瓣膜不匹配者密切超声随访。
  • 再干预时,缝合less Perceval可能适合小自体瓣环;瓣中瓣TAVI因有效开口面积减小风险仅限选择病例。

临床怎么用

  • 对Trifecta植入后高危患者(肾功能受损、低EOA指数、PPM)加强超声随访以早期发现衰败。
  • 再干预策略需根据自体瓣环大小选择:小瓣环可考虑Perceval,大瓣环选择病例可考虑瓣中瓣TAVI。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Aortic valve replacement with Trifecta valve provides a greater early haemodynamic performance with its externally mounted structure. However, failure rates in short-term post-implantation started to be reported, which brought great attention towards understanding the mechanisms of failure and optimal approaches for the replacement of the valve. METHODS: Fifty-seven studies published in PubMed/Medline, Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and ClinicalTrials.gov were explored until January 2025. Original research articles or clinical trial reports that describe Trifecta failure and studies that describe valves used to approach failed Trifecta valves were included. RESULTS: Durability of Trifecta has shown a median range of 4 to 9 years with re-operative incidence of 7.3% to 16.9%, respectively, with smaller valves (19-21 mm) degenerating quicker. Anti-calcification compounds used and valve design are the main causes for Trifecta structural valve degeneration. Modes of Trifecta failure soon after valve implantation are leaflet(s) dehiscence or tear along the stent post and, in the longer term post-operatively, include leaflet calcification and the fibrofatty circumferential pannus development in the inflow area. CONCLUSIONS: We recommend that patients following Trifecta implantation with preoperative impaired kidneys, postoperative low effective orifice area (EOA) indexes, and prosthesis-patient mismatch be closely followed with echocardiograms to detect a possible Trifecta failure. Replacing a failed Trifecta valve with a sutureless Perceval could be an excellent option to approach a pre-existing small native annulus. Valve-in-valve transcatheter aortic valve implantation is a less favourable option due to the risk of a reduced EOA, though it may still be considered in selected patients with larger annuli.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Nezafati P, Azari M, Yadav S, et al. Mechanisms of Trifecta Valve Failure and Contemporary Approaches to Reintervention: Perceval vs Valve-in-Valve Transcatheter Aortic Valve Implantation. Interdiscip Cardiovasc Thorac Surg. 2026. PMID: 41502003. doi:10.1093/icvts/ivaf234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。